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Anti-TNF therapy successfully induces clinical remission and improvement in quality of life in many patients affected by autoinflammatory disorders, such as psoriasis, rheumatoid arthritis (RA), and inflammatory bowel disease (IBD). [1] [2] [3] Paradoxically, anti-TNF treatment of both patients with IBD and those with RA has been associated with unexpected side effects, such as a psoriasis-like syndrome. 4, 5 This suggests that depletion of TNFa might inadvertently trigger specific forms of immune pathology and highlights the pleiotropic nature of TNF-a. This feature has thus far received limited attention. Relevant in this respect is the finding that anti-TNF agents are capable of promoting IL-17 expression in CD4 1 T-cell lines from patients with juvenile idiopathic arthritis 6 and those with RA 7, 8 and can promote monocytedriven IL-17 production of T cells. 7 Because IL-17 is a potent proinflammatory cytokine responsible for the pathogenesis and progression of psoriasis and many other autoimmune disorders, this might explain some of the above mentioned clinical findings. Importantly, the molecular mechanism behind the anti-TNFmediated induction of IL-17 by T cells is as yet not understood, and the phenomenon has not been evaluated clinically.
TNF-a is present in 2 forms: membrane-bound uncleaved TNF-a (approximately 75 kDa) and soluble cleaved TNF-a (approximately 55 kDa). TNF-a signaling through TNF receptor (TNFR) 1 or TNFR2 on immune cells primarily activates nuclear factor kB (NF-kB) and promotes transcription of genes related to inflammatory processes, such as proliferation, cytokine production, and cell survival. 9 Notably, NF-kB activation also results in expression of anti-inflammatory regulators, such as TNF-ainduced protein 3 (TNFAIP3), which encodes the deubiquitinating enzyme A20, 10 a renowned negative regulator of NF-kB activation. 11, 12 This NF-kB-induced TNFAIP3/A20 negative feedback loop was studied mostly in innate immune cells, 13 but there are indications that TNFAIP3/A20 also negatively regulates CD4 T cells. 14 Polymorphisms in the TNFAIP3 gene or region have been associated with several autoimmune diseases [15] [16] [17] [18] and also anti-TNF responsiveness in patients with IBD and psoriasis, 19, 20 which suggests an undetermined relationship between the lack of TNF-a signaling, deviant TNFAIP3/A20 expression, and immune activity.
Here we present evidence that TNFAIP3/A20 acts as a master switch in TNF-a blockade-driven IL-17A expression in human CD4
1 T cells and show an inverse relationship between TNFAIP3/A20 expression levels and IL-17A-expressing T cells. In an ex vivo study of patients with IBD treated with the anti-TNF biosimilar remsima, we found further evidence for the role of TNFAIP3/A20 by showing that low mRNA levels of TNFAIP3 were associated with increased IL-17A expression. In reverse, patients with high TNFAIP3 mRNA levels after Remsima treatment showed low IL-17 expression; most of these patients carried the heterozygous TNFAIP3/A20 region variant genotype C>G (rs6927172), which has been related to increased TNFAIP3/A20 expression. 19 Our results suggest that combined analysis of TNFAIP3 mRNA expression, TNFAIP3 region polymorphisms, and IL-17A production by CD4
1 T cells can aid in the design of future patient risk stratification protocols in anti-TNF therapy. Moreover, it provides novel targets for additional improved therapeutic regimens in patients with IBD.
METHODS

Study approval
The protocols of this study were performed in agreement with the Declaration of Helsinki and approved by the Institutional Review Board of Radboud University Medical Center in Nijmegen (Radboud UMC), the Netherlands (registration code: 2015-1838).
Subjects
Voluntary blood donors (Sanquin Bloedvoorziening, Nijmegen, The Netherlands) and healthy volunteers (n 5 31) and patients (n 5 12) provided written informed consent. Patients with IBD (ie, ulcerative colitis or Crohn disease) were naive for any biological drug treatment. For more detailed information on the patients, see Table E1 in this article's Online Repository at www.jacionline.org. The clinical evaluation of patients with IBD was based on disease indexes, including the Harvey Bradshaw Index for Crohn disease and the Simple Clinical Colitis Activity Index for ulcerative colitis. 21 
PBMC and T-cell isolation
Fresh PBMCs collected in tubes with acid citrate dextrose and derived from healthy blood donors and patients with IBD were isolated by using FicollPaque density gradient centrifugation. CD4
1 T cells were isolated from whole blood by using the RosetteSep CD4 Enrichment Cocktail (25- 
Cell culture
RPMI 1640 (Gibco, Carlsbad, Calif) culture medium (Dutch modification) with sodium bicarbonate and 20 mmol HEPES and supplemented with penicillin/streptomycin (100 U/mL), sodium pyruvate (1 mmol), glutamine/ GlutaMAX and 10% human pooled serum (Radboud UMC) was used in all experiments. After cell isolation, 2.5 3 10 4 cells/well were cultured in 96-well U-bottom plates and incubated with Dynabeads Human T-Activator CD3/ CD28 (1:5 bead/cell ratio; Gibco) and recombinant human IL-2 (rhIL-2; 100 U/mL Proleukin; Prometheus Laboratories, San Diego, Calif). Where indicated, cultures were supplemented with recombinant human TNF-a (rhTNF-a; 50 ng/mL; R&D Systems, Minneapolis, Minn), recombinant human lymphotoxin-a (10 ng/mL; R&D Systems), or the TNF-a inhibitors (5 mg/mL) etanercept (Enbrel; Pfizer, New York, NY), infliximab (Remicade; Janssen Biotech, Raritan, NJ), or adalimumab (Humira; AbbVie, Chicago, Ill); remsima (Remsima, Celltrion, Seoul, Korea); TNFR2 agonist (2.5 mg/mL; MR2-1; Hycult Biotech, Plymouth Meeting, Pa); anti-human TNFR1 (10 mg/mL; anti-human CD120a; H398; eBioscience, San Diego, Calif); anti-human TNFR2 (10 mg/mL; anti-human CD120b; 3G7A02; BioLegend, San Diego, Calif); recombinant human IgG 1 (AbD18705_hIgG1; Bio-Rad Laboratories, Hercules, Calif); mouse IgG 1 (11711; R&D Systems), or CysTNFR2 (50 ng/mL) with the mAb 80M2 (2 mg/mL). 22 Isolated cells were preincubated for 30 minutes before stimulation to examine the effect of pharmaceutical inhibitors of protein kinase C (PKC; AEB071; 10 mmol sotrastaurin; Novartis, Basel, Switzerland) or p38a/b kinase (50 mmol UR13870, previously known as ORG48762-0; Palau Pharma, Barcelona, Spain).
23,24
Flow cytometry
Flow cytometry was performed with a 10-color Navios Flow cytometer (Beckman Coulter). To evaluate cytokine production, we restimulated PBMCs and CD4
1 T-cell subsets for 4 hours with phorbol 12-myristate 13-acetate (12.5 ng/mL), ionomycin (500 ng/mL), and Brefeldin A (5 mg/mL; SigmaAldrich, St Louis, Mo). After incubation, in some cases the cells were stained with Fixable Viability Dye-APC-780 (eBioscience) for 30 minutes, followed by surface staining, fixation/permeabilization (Intracellular Fixation & Permeabilization Buffer Set; eBioscience), and intracellular staining.
Measurement of cell-culture cytokines
Cell-culture supernatants were analyzed for the presence of IL-17A, IFN-g, and TNF-a by using Bio-Plex Pro Human Th17 Cytokine Assays (Bio-Rad Laboratories), according to the manufacturer's instructions. Cytokine concentrations were measured with a Luminex 100 (Luminex, Austin, Tex) and analyzed by using the software Bio-Plex 6.1 (Bio-Rad Laboratories). The lower level of detection was 1.9 pg/mL for IL-17A, 11.5 pg/mL for IFN-g, and 2.2 pg/mL for TNF-a.
Western blotting
To detect A20 protein in cultured CD4 
Quantitative real-time PCR
Total RNA was extracted by using the RNeasy Plus Micro Kit (Qiagen, Hilden, Germany), followed by cDNA synthesis with the SuperScript III FirstStrand Synthesis System and Oligo(dT)20 primers (Thermo Fisher Scientific). TaqMan gene expression assays were purchased from Thermo Fisher Scientific (see Table E2 in this article's Online Repository at www.jacionline.org).
Single nucleotide polymorphism genotyping
DNA was isolated by using the QIAamp DNA Blood Mini Kit (Qiagen), according to the manufacturer's protocol. Single nucleotide polymorphism (SNP) genotyping of rs6927172 (for SNP details, see Fig E1 in this article's Online Repository at www.jacionline.org) was performed with TaqMan SNP Genotyping Assays on an ABI 7500 System, according to the manufacturer's instructions, by using the SNP rs6927172 assay C_1575580_10 (Thermo Fisher Scientific). PCR results were analyzed with 7500 Fast System SDS software (version 1.5; Thermo Fisher Scientific).
RNA sequencing
An initial quality check of RNA quantification of the samples was performed by using capillary electrophoresis with the LabChip GX (PerkinElmer, Waltham, Mass). Nondegraded RNA samples were selected for subsequent sequencing analysis. We carried out differentially expressed gene (DEG) analysis using DESeq2, in which donor and batch effect sample preparation were controlled in the model. Principal component analysis was carried out to visualize the samples given their entire transcriptome and any remaining batch effects (see Fig E2 in 
Small interfering RNA transfection
For small interfering RNA (siRNA) knockdown of TNFAIP3, Accell SMARTpool siRNA (Dharmacon, Lafayette, Colo) was used according to the manufacturer's instructions. Briefly, 5 3 10 4 CD4 1 Tmem cells per well were stimulated with aCD3/CD28 beads (1:5 bead/cell ratio) in human serum-free Accell Delivery Medium (Dharmacon) and incubated with Accell siRNA buffer or 1 mmol cyclophilin B (positive control), nontargeting siRNA, or TNFAIP3 siRNA for 6 days (for siRNA sequences, see Table E3 in this article's Online Repository at www.jacionline.org). Quantitative real-time PCR (RT-qPCR) and FACS analysis were performed to confirm the knockdown and cytokine expression in CD4 1 Tmem cells.
Statistical analysis
Statistical analysis was performed with GraphPad Prism software (5.0 for Windows; GraphPad Software, La Jolla, Calif) and R statistical language software. For statistical analysis of experiments with more than 2 groups, a Friedman test followed by Dunn multiple comparison was used, whereas the Wilcoxon matched-pairs signed-rank test was used in case of experiments consisting of 2 groups. For correlation analysis, we applied the Spearman rank correlation coefficient. A method based on negative binomial distribution (DESeq2) was used to test for significant differences in gene expression for RNA sequencing (RNA-seq) analysis.
For a detailed description of the materials and methods used in this study, see the Methods section in this article's Online Repository at www.jacionline. org.
RESULTS
Anti-TNF blockade promotes IL-17A expression by CD4
1 T cells in vitro and in vivo in patients with inflammatory bowel disease
The effect of TNF blockade on the function of T lymphocytes is barely understood. Therefore we first evaluated the in vitro effect of anti-TNF treatment on the proinflammatory cytokineproducing potential of aCD3/CD28-stimulated PBMCs from healthy blood donors and patients with IBD, thereby focusing on CD4
1 T cells. In a first approach, we compared the effects of different clinically used TNF-a antagonists (infliximab, adalimumab, and etanercept). Inhibition of TNF-a, irrespective of the anti-TNF agent tested, resulted in a significantly increased percentage of IL-17A-expressing (P < .001), IFN-g-expressing (P < .01), and IL-17A/IFN-g-expressing (P < .01) CD4
1 T cells from healthy subjects (Fig 1, A and B) .
Because all TNF-a antagonists tested induced this same phenomenon, we further focused on etanercept in subsequent analyses. Using etanercept, we observed that the in vitro anti-TNF-induced increase in IL-17A and IFN-g expression was also observed in CD4
1 T cells from patients with IBD before the start of therapy (Fig 1, C) . Also, anti-TNF induced IL-17 in a long-term kinetic assay (see Fig E3 in this article's Online Repository at www.jacionline.org).
To verify whether in vivo treatment with anti-TNF agents of patients with inflammatory disorders revealed a similar phenomenon, we analyzed ex vivo cytokine expression using PBMCs of patients with IBD (n 5 12) treated for 6 weeks with anti-TNF (Remsima). Although a significant increase in IL-17-expressing cells was previously observed in patients with RA and ankylosing spondylitis, 7, 8, 25 we did not observe a significant increase in absolute numbers of IL-17A-expressing CD4 1 T cells from patients with IBD but did note that 50% of the patients had a clear increase in the number of IL-17A-expressing CD4
1 T cells (Fig 1, D) , whereas the other patients showed a clear reduction in IL-17A expression after anti-TNF treatment (Fig 1, D) . Patients who revealed an increase in IL-17A expression did not show an increase in numbers of IFNg-expressing cells (see Fig E4 in this article's Online Repository at www.jacionline.org). Moreover, patients who showed an increase in IL-17A expression after anti-TNF treatment seem to show a better clinical response compared with patients with a reduction in IL-17A expression (Fig 1, D , and see Table E1 ).
Anti-TNF blockade promotes IL-17A production exclusively through ablation of TNF-a signaling in activated Tmem cells
In addition to CD4
1 T cells, PBMCs contain other adaptive and innate immune cells that might also be influenced by anti-TNF Based on the ex vivo IL-17A expression in PBMCs detected after 4 hours of restimulation with phorbol 12-myristate 13-acetate and ionomycin in the presence of Brefeldin A, the patients were grouped into those who showed reduced (IL-17Y) or increased (IL-17[) IL-17A expression after Remsima treatment (middle graphs), followed by their clinical response (lower graph). All data are shown as means 6 SEMs. For statistical analysis, the Friedman test followed by the Dunn multiple comparison test, the Wilcoxon matchedpairs signed-rank test, and 2-way ANOVA were used: *P < .05 and **P < .01. ns, Not significant.
agents. To demonstrate that anti-TNF-mediated cytokine production of CD4 1 T cells was a direct consequence of the anti-TNF agent acting on CD4
1 T cells, we FACS-sorted Tnaive and Tmem cells based on surface expression of CD45RA and CD25 and cultured the cells under aCD3/CD28 stimulation in the presence of rhIL-2 with and without anti-TNF treatment and analyzed IL-17A and IFN-g expression (Fig 2, A) . In isolated Tmem cells but not Tnaive cells, anti-TNF treatment induced a significant increase in single IL-17A-producing (P < .001), single IFNg-producing (P < .002), and double-positive IL-17A/IFNg-producing T cells (P < .0036 ; Fig 2, 1 Tmem cells led to a significant reduction in the percentage of IL-17A-, IFN-g-, and IL-17A/IFN-g-producing T cells compared with the untreated conditions (Fig 2, C) .
Likewise, supplementation with recombinant human lymphotoxin-a, a member of the TNF superfamily that shares amino acid sequence homology with TNF-a and is known to activate the same signaling pathways as TNF-a, 26 also inhibited IL-17A expression by CD4
1 Tmem cells (see Fig E7 in this article's Online Repository at www.jacionline.org).
In addition to the observed increase in IL-17A intracellular expression on anti-TNF treatment, both IL17A and IL17F mRNA expression levels (Fig 2, D) , as well as IL-17A cytokine secretion in culture supernatants, were also increased (see Fig E8, A, in this article's Online Repository at www.jacionline.org). This was observed for neither IFNG mRNA expression (Fig 2, D) nor IFN-g secretion (see Fig E8, B) . The T H 17-and T H 1-associated transcription factors RORC (encoding retinoic acid-related orphan receptor gt) and TBX21 (encoding T-bet) were both upregulated by anti-TNF treatment (Fig 2, D) . These data indicate that anti-TNF treatment promotes a preferential shift toward a T H 17 phenotype.
TNF-a, either soluble TNF or membrane-bound TNF (mTNF), signals through TNFR1, TNFR2, or both, which ultimately results in NF-kB activation. 27 To confirm that etanercept promotes IL-17A expression through inhibition of TNF-a signaling and not through mTNF-mediated reverse signaling, we evaluated etanercept binding to CD4
1 Tmem cells in our in vitro system by using flow cytometry and demonstrated that etanercept does not bind to Tmem cells (see Fig E9 in this article' s Online Repository at www.jacionline.org). This indicates that etanercept promotes IL-17A production of in vitro-activated CD4
1 Tmem cells through prevention of TNF-a signaling rather than through mTNF-mediated reverse signaling.
TNF-a signaling regulates IL-17A production in Tmem cells through TNFR2
Next, we examined which of the TNFRs is primarily involved in the TNF-a-mediated IL-17A regulation of CD4
1 Tmem cells. First, we evaluated TNFR1 and TNFR2 surface expression on CD4
1 Tmem cells on aCD3/CD28 stimulation. Freshly isolated CD4
1 Tmem cells hardly expressed either TNFR1 or TNFR2, whereas the majority of the cells showed high expression of TNFR2 after 5 days of activation; TNFR1 expression at that time point was barely detectable, suggesting that TNFR2, but not TNFR1, might play a critical role in CD4
1 Tmem (see Fig  E10 in this article' s Online Repository at www.jacionline.org). To assess through which receptor TNF-a influences the IL-17A-producing potential of CD4
1 Tmem cells, we isolated and stimulated CD4
1 Tmem cells with aCD3/CD28 and rhIL-2 in the absence or presence of specific TNFR1 or TNFR2 antagonists. Only TNFR2 inhibition led to an increase in IL-17A expression (Fig 3, A and B) . However, activation of TNFR2 with specific TNFR2-agonistic antibody (Fig 3, A and B) or TNFR2-selective TNF ligands (cysTNFR2) in the presence of the TNFR2-specific antibody mAb 80M2 (Fig 3, A and B) , which ensures full TNFR2 activation, 22 led to a reduction in IL-17A expression (Fig 3, A and B) , confirming that TNFR2 signaling plays a crucial role in anti-TNF-mediated IL-17 expression.
Induction of NF-kB activation is one of the main outcomes of TNF-a-mediated TNFR signaling. 28 Anti-TNFR2 treatment or etanercept, in contrast to TNFR2 agonist or rhTNFa, led to strong inhibition of the transcription of the NF-kB target genes RELB (Relb), NFKB1 (p50), NFKB2 (p52), and NFKBIA (IkBa; Fig  3, C and D) .
Together, these data demonstrate that TNFR2 signaling plays a significant role in the regulation of IL-17A production in CD4 1 Tmem cells. Moreover, because anti-TNF agents suppress the activation of NF-kB signaling pathways, NF-kB does not seem to directly take part in the enhanced expression of IL-17 by CD4
1 Tmem cells after anti-TNF treatment. At the same time, this suggests that NF-kB might be involved in affecting factors or processes that negatively regulate IL-17 expression.
TNF blockade suppresses TNFAIP3/A20 expression, which is associated with enhanced IL-17A expression in activated CD4
1 Tmem cells
For a more in-depth exploration of factors involved in the increased IL-17A expression induced by anti-TNF supplementation of aCD3/CD28-stimulated CD4
1 Tmem cells, whole-genome RNA sequencing was performed. Because supplementation of rhTNF-a reduced the IL-17A-secreting potential of CD4
1 Tmem cells, this condition was coanalyzed to establish differential gene expression between both conditions. The comparative analysis of CD4
1 Tmem cells exposed to anti-TNF (etanercept) versus rhTNF-a revealed opposing transcriptional profiles (Fig 4, A) . Of the 751 DEGs (false discovery rate 5 0.05) between rhTNF-a and anti-TNF comparison (for the full DEG list, see Table E4 in this article's Online Repository at www.jacionline.org), TNFAIP3, NFKBIA (IkBa), RELB (Relb), BIRC2 (baculoviral IAP repeat containing 2), and LTA (lymphotoxin a) were suppressed by anti-TNF-a (Fig 4, B) , whereas AQP3 (aquaporin 3), SLFN5 (Schlafen family member 5), IL7R (IL-7R), APOL4 (apolipoprotein L4), and ITGA6 (integrin a6) were significantly upregulated (Fig 4, B) .
The deubiquitinating enzyme TNFAIP3/A20 is a well-known negative regulator of NF-kB activation.
11,12 Activation of NF-kB (ie, by TNF-a) enables translocation of NF-kB into the nucleus and subsequent target gene activation and protein expression, including the anti-inflammatory regulator TNFAIP3/A20.
10
The deubiquitinating activity of TNFAIP3/A20 ultimately avoids the assembly of proximal NF-kB-activating complexes and stops the inflammatory response, triggering an NF-kB autoregulatory negative feedback loop. 29 Therefore, of the DEG with a fold J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 2 1 Tmem cells that were stimulated as indicated in the presence of rhTNF-a (n 5 11). D, Relative mRNA expression levels of IL17A, IL17F, IFNG, RORC, and TBX21 in CD4 1 Tmem cells that were cultured as indicated and measured by using RTqPCR (n 5 8). All data are shown as means 6 SEMs. For statistical analysis, the Friedman test followed by the Dunn multiple comparison test, Wilcoxon matched-pairs signed-rank test, and 2-way ANOVA were used. *P < .05, **P < .01, and ***P < .01. ns, Not significant.
change of 2 or greater (red dot plots) from the total of 751 genes identified, we focused on regulation of TNFAIP3/A20 by anti-TNF because TNFAIP3 is implicated in the pathology of several autoimmune diseases. [15] [16] [17] [18] Moreover, TNFAIP3/A20 has been shown to negatively regulate CD4
1 T-cell activation.
14 Using RT-qPCR, we confirmed that anti-TNF (etanercept) supplementation to cultures of aCD3/CD28-stimulated CD4 1 Tmem cells suppressed TNFAIP3 mRNA, whereas on the contrary, T-cell activation in the presence of rhTNF-a induced TNFAIP3 transcription (Fig 4, C) . Also, we demonstrated that 1 IL-17A-expressing cells (Fig 3, A) and cumulative data showing intracellular IL-17A 1 expression in CD4 1 Tmem cells after restimulation with phorbol 12-myristate 13-acetate and ionomycin in the presence of Brefeldin A (Fig 3, B; n 5 6-9). C and D, Relative mRNA expression measured by using RT-qPCR of NF-kB target genes in CD4 ETN] ). All data are shown as means 6 SEMs. The Friedman test followed by the Dunn multiple comparison test and Wilcoxon matched-pairs signed-rank test were used for statistical analysis. *P < .05 and **P < .01. ns, Not significant. ; Fig 4, I) . DESeq2, Friedman test followed by the Dunn multiple comparison Test, the Wilcoxon-Mann-Whitney U test, and the Spearman test were used for statistical analysis. *P < .05 and **P < .01. ns, Not significant.
TNFAIP3 mRNA expression correlated inversely with IL17A expression (Spearman test, r 5 20.7789, P < .001) in activated CD4 1 Tmem cells on anti-TNF and rhTNF-a treatment (Fig 4,  D) . Then we analyzed whether the observed downregulation of TNFAIP3 by anti-TNF (etanercept) also resulted in reduced protein expression of its cognate protein A20 (approximately 87 kDa). To this end, isolated CD4
1 Tmem cells were stimulated with aCD3/CD28 beads, and rhIL-2 was added exogenously in the presence or absence of rhTNF-a or anti-TNF (etanercept), and after 5 days of culture, cells were harvested and prepared for Western blot analysis. Anti-TNF treatment clearly inhibited TNFAIP3/A20 protein expression, whereas conversely, the addition of rhTNF-a led to a significant increase of TNFAIP3/A20 (Fig 4, E) , and see Fig E11 in this article' s Online Repository at www.jacionline.org.
To reveal a direct relationship between suppression of TNFAIP3/A20 and increased IL-17A expression, we used an siRNA approach to knockdown TNFAIP3/A20 in 
isolated CD4
1 Tmem cells. We demonstrate that TNFAIP3 siRNA resulted in significantly enhanced percentages of IL-17A-expressing cells (Fig 4, F) . Using RT-qPCR, we confirmed that TNFAIP3 siRNA inhibition led to suppression of TNFAIP3/A20 mRNA expression (Fig 4, G) . The data implicate TNFAIP3/A20 as an essential regulator of IL-17A in CD4
1 Tmem cells and reveal the association between anti-TNF-mediated repression of TNFAIP3/A20 and enhancement of IL-17A expression. Moreover, in patients with IBD who showed increased IL-17A production after anti-TNF therapy (Fig 1, D) , we found a reduced frequency of the heterozygous TNFAIP3/A20 region variant genotype C>G (rs6927172 ; Fig 4,  H) , which has been shown to increase TNFAIP3 expression in patients with IBD, 19 corroborating the reduced TNFAIP3/A20 mRNA expression in CD4
1 Tmem cells (Fig 4, I) . These observations further support the clinical relevance of our finding; that is, deviant TNFAIP3/A20 expression plays an important role in IL-17A expression by CD4
1 Tmem cells through downmodulation of TNF-a-mediated signaling.
PKC and p38 mitogen-activated protein kinase signaling are required for anti-TNF-mediated enhancement of IL-17A expression in stimulated Tmem cells
In the experiments above, we stimulated T cells by triggering both the T-cell receptor (TCR; CD3) and costimulatory receptor CD28 by using aCD3/CD28 beads. PKC-u signaling, which plays an important role in T-cell activation through aCD3/CD28 activation 30 has also been implicated in regulation of the biological activity of A20 in activated T cells and vice versa.
14 Furthermore, PKC signaling has also been shown to contribute to IL-17 production in mouse T cells 31 and human CD4 1 regulatory T cells. 32 Interestingly, in our RNA-seq analysis (see Table  E4 ) we observed that anti-TNF treatment induced expression of PRKCQ (encoding PKC-u) in aCD3/CD28-stimulated CD4
1
Tmem cells, which we confirmed by using RT-qPCR (Fig 5, A) . We hypothesized that inhibition of the PKC signaling of CD4 1 Tmem cells, which was activated in the presence of etanercept/ aCD3/CD28 beads, might prevent the anti-TNF-mediated increase in IL-17A expression. Supplementation of the pan-PKC inhibitor AEB071 (sotrastaurin) to CD4
1 Tmem cells that were activated by aCD3/CD28 beads in the presence of anti-TNF (etanercept) prevented the anti-TNF-mediated increase in IL-17A expression (Fig 5, B and C) . These results suggest that PKC signaling, most likely as a consequence of TCR and CD28 costimulation, plays an important role in the anti-TNF-mediated increase in IL-17A expression. However, it is not likely that proximal PKC signaling is the main driver of anti-TNF-mediated IL-17 expression in these activated T cells, but rather, more distal signaling pathways will be involved.
To further explain the enhanced IL-17A expression by anti-TNF treatment, we focused on the mitogen-activated protein kinase (MAPK) signaling pathway because TNFAIP3/A20 has been implicated in negative regulation of the p38 MAPK inhibitor, 33 and recently, p38 was shown to control IL-17 expression in mouse CD4 1 T cells. 34 Small-molecule p38 MAPK inhibitor in CD4
1 Tmem cells activated in the presence of anti-TNF (etanercept) prevented the anti-TNF-mediated increase in IL-17 expression (Fig 5, B and D) . This indicates that p38 signaling is vital in anti-TNF-mediated enhancement of IL-17A expression. is secreted (2) and signals through TNFR2 to promote NF-kB expression (3), which leads to high expression of the anti-inflammatory mediator A20 (4), which is known to act as a negative feedback loop to suppressing NF-kB (5). Our results indicate that A20 can inhibit p38MAPK and PKC activity (6) and prevents IL-17A (7) expression. B, Anti-TNF inhibits TNF-a signaling through TNFR2 (2), and as a consequence, A20 is not expressed (4). Lack of A20 impairs the NF-kB negative feedback loop (5) and endorses PKC and p38 MAPK signaling (6), inducing expression of IL-17 (7). C, Stratification of anti-TNF responsiveness in patients with IBD (blue represents the group of patients with high IL-17 expression after anti-TNF treatment, and red represents the group of patients with low IL-17 expression after anti-TNF treatment) based on intracellular IL-17A production by T cells, followed by TNFAIP3 mRNA expression and polymorphisms.
In summary, prevention of TNF-a signaling by anti-TNF in aCD3/CD28-stimulated CD4
1 Tmem cells results in increased IL-17A production through inhibition of the anti-inflammatory mediator TNFAIP3/A20. Under these circumstances, PKC and p38 MAPK are crucial for the production of IL-17A. On the basis of our findings and as depicted in Fig 6, we propose a model showing the molecular pathways involved in anti-TNF treatment-mediated enhancement of IL-17A expression in CD4 1 T cells.
DISCUSSION
Anti-TNF therapy is successful in many patients with inflammatory disorders, 35 but anti-TNF therapy is also associated with adverse effects, such as the unexplained psoriasis-like syndrome. 4, 36 These paradoxical observations after inhibition of TNF-a signaling might be explained by the pleiotropic nature of TNF-a, which displays both inflammatory and antiinflammatory bioactivities. 5 Thus far, more detailed mechanistic insight into how these phenomena are induced is limited, and clinical data supporting such findings are lacking.
Here we present novel insights showing that inhibition of TNFa signaling by anti-TNF agents in activated Tmem cells prevents expression of the anti-inflammatory mediator TNFAIP3/A20, which consequently promotes IL-17A production. This process requires PKC and p38 MAPK signaling.
TNFAIP3/A20 is a ubiquitin-editing enzyme consisting of an A20-type zinc finger and an OTU domain, which mediates ubiquitin ligase and deubiquitinase activity, respectively.
33
TNFAIP3/A20 acts as a negative feedback mechanism mainly by preventing NF-kB activation through deubiquitination or ubiquitination of a multitude of proteins, such as RIP1. 37 Although it is well established that TNFAIP3/A20 regulates TNF-a signaling, 38 TNFAIP3/A20 has been shown to regulate multiple other immune pathways, including Toll-like receptor signaling, [39] [40] [41] IL-17 receptor signaling, 33 Wnt signaling, 42 TCR signaling, 14 and MAPK signaling. 33 Not surprisingly, loss of TNFAIP3/A20 expression causes spontaneous inflammatory and autoimmune diseases in mice, 43 and polymorphisms or mutations in the TNFAIP3 gene or region that affect A20 expression or function are related to a variety of autoimmune diseases in human subjects. 13 Interestingly, clinical studies showed that TNFAIP3 region polymorphisms are associated with therapeutic efficacy of anti-TNF treatment in patients with IBD, as well as those with psoriasis, 19, 20 indicating an unresolved relationship between the lack of TNF-a signaling, deviant A20 expression, and immune activity. Here, using RNA-seq and Western blot analyses, we add to the understanding of this relationship by demonstrating that anti-TNF treatment prevents transcription and expression of the anti-inflammatory mediator TNFAIP3/ A20 in activated CD4
1 Tmem cells and subsequently provide evidence that siRNA inhibition of TNFAIP3 results in increased IL-17A expression.
The effect of TNFAIP3/A20 ablation on the exacerbated expression of IL-17A by CD4
1 Tmem cells after anti-TNF therapy in the clinical setting is still unknown. Here, in a small cohort of patients with IBD treated with the anti-TNF biological agent Remsima, we showed an inverse relationship between numbers of IL-17A-expressing CD4
1 Tmem cells and a reduction of TNFAIP3/A20 mRNA expression, supporting our in vitro findings. Notably, patients with IBD treated with Remsima showing increased numbers of IL-17A-expressing CD4
1 T cells on treatment seemed to have a better clinical response. Also, this group revealed a lower frequency of the heterozygous TNFAIP3 region variant genotype C>G (rs6927172), which previously was shown to increase TNFAIP3/A20 expression and was associated with nonresponsiveness to anti-TNF therapy in patients with IBD. 19 These findings clearly suggest a link between IL-17A expression by CD4
1 T cells, TNFAIP3/A20 region polymorphisms, TNFAIP3 expression levels, and clinical responsiveness to anti-TNF therapy. To firmly establish this link, further studies are needed.
Until now, a relationship between TNFAIP3/A20 expression and IL-17A production by activated T cells had not been established. On T-cell stimulation, TNFAIP3/A20 is strictly regulated to control the process of T-cell activation; TNFAIP3/A20 is highly expressed in resting CD4
1 T cells and rapidly depleted after TCR/ CD28 stimulation 14 in a process involving both PKC-u and paracaspase MALT1 activity, 44, 45 which ultimately leads to activation of NF-kB. However, under persistent stimulation, TNFAIP3/A20 is restored and abolishes TCR and NF-kB signaling.
14 Our data reveal that inhibition of TNFAIP3 expression, either through blocking of TNF-a or TNFAIP3 knockdown, in activated CD4
1
Tmem cells results in increased IL-17A expression in vitro. To our knowledge, this link between TNFAIP3/A20 and IL-17 has not been described before. However, from mouse studies, it is known that A20 can prevent MAPK activity, 33 whereas p38 MAPK activity appeared essential for IL-17 production by CD4 1 T cells in an experimental allergic encephalomyelitis model. 34 Although we did not evaluate the direct relation between inhibition of A20 and p38 MAPK activity in our experiments, our data show that p38 MAPK inhibition prevented anti-TNF-mediated enhancement of IL-17A expression by activated CD4 1 Tmem cells. Together, this supports the possibility that ablation of TNFAIP3/A20 by anti-TNF treatment endorses p38 MAPK activity, thereby promoting IL-17A expression in CD4
1 Tmem cells.
In addition to its function as a regulator of TCR signaling in T-cell activation, there is strong evidence that TNFAIP3/A20 is an important negative regulator of activation of antigenpresenting cells (APCs) in mice. 46 Anti-TNF treatment was shown to result in much stronger production of IL-17 in an in vitro experimental setup in which human T cells were stimulated with aCD3 mAb plus monocytes compared with T cells that were activated with aCD3/CD28 stimulation beads only. 7 This indicates that the presence of APCs boosts IL-17 expression even further after depletion of TNF-a by anti-TNF agents. A possible explanation for this increased IL-17 expression on monocyte coculture is that anti-TNF agents might suppress TNFAIP3/A20 expression in these APCs, resulting in hyperactivated APCs that in turn provoke hyperstimulation of CD4 1 Tmem cells, thereby triggering high IL-17 expression. In fact, TNFAIP3/A20 deprivation of dendritic cells (DCs) in mice led to exacerbated DC activation, and these DCs strongly promoted overproduction of IL-17 by mouse wild-type T cells in vitro. 47 A limitation of our work is that we only focus on T cells as a source of TNF-a, but obviously, there are many other cellular sources of TNF-a 48 that are influenced by anti-TNF treatment. In addition to T cells, other immune cell types, such as basophils and type 3 innate lymphoid cells, were associated with IBD.
49,50
J ALLERGY CLIN IMMUNOL VOLUME 142, NUMBER 2 In which ways might our findings that TNFAIP3/A20 acts as a master switch in TNF-a blockade-driven IL-17A expression add to improved clinical regimens? IL-17A-producing T cells are strongly associated with various inflammatory diseases. [51] [52] [53] It could well be that the anti-TNF therapy-associated reduction in TNFAIP3/A20 expression and its resultant increase in numbers of IL-17A-expressing T cells contributes to the immune pathology of paradoxical autoimmune-related side effects, such as psoriasis-like syndrome, that are observed in 0.6% to 5% of the patients treated with anti-TNF medication. 4 Of interest, in pilot experiments we observed that Tmem cells of patients with IBD with a psoriasis-like syndrome after anti-TNF treatment in the past revealed reduced TNFAIP3/A20 mRNA expression levels and an increased potential to express IL-17A compared with healthy control subjects or patients with IBD who did not have psoriasis-like syndrome (see Fig E12 in this article' s Online Repository at www.jacionline.org). TNFAIP3/A20 has been shown to prevent p38 MAPK activity in a mouse model, 34 and here we demonstrate that anti-TNF-induced inhibition of TNFAIP3/A20 promotes IL-17A expression by facilitating p38 MAPK activity. Although speculative, anti-TNF treatment combined with specific p38 MAPK inhibition might prevent the anti-TNF-associated paradoxical autoimmune side effects. In addition, our data suggest that IL-17A expression and reduced TNFAIP3/A20 mRNA levels by activated CD4
1 T cells might contribute to better clinical response in patients with IBD treated with anti-TNF.
Although IL-17A is renowned for its proinflammatory potential, IL-17 has also been shown to be beneficial in epithelial barrier protection in patients with IBD. [54] [55] [56] [57] Additional support for a protective role of IL-17A in patients with IBD emerged from a placebo-controlled anti-IL-17A mAb clinical trial in patients with Crohn disease, in which it was reported that a substantial number of the patients had exacerbation of disease. 58 Although anti-IL-17 inhibition was not successful in patients with IBD, small-molecule inhibition of retinoic acid-related orphan receptor gt, a crucial transcription factor for T H 17 cell differentiation, might be an alternative approach for the treatment of IBD. 59 Moreover, in addition to anti-TNF inhibition, other biological agent-based therapeutics, such as adhesion molecule inhibition, have been applied successfully in patients with IBD. 60 Based on our current work, we propose that combined analysis of TNFAIP3 mRNA expression, TNFAIP3 region polymorphisms, and IL-17A production by CD4
1 T cells might aid in the design of future patient risk stratification protocols in anti-TNF therapy. Moreover, it provides novel TNFAIP3/A20 activity-related targets for additional improved therapeutic regimens in patients with IBD.
In conclusion, we add to the understanding of the biological effects of anti-TNF therapy by demonstrating that TNF blockade interferes in an autocrine anti-inflammatory regulatory feedback loop with TNFAIP3/A20 at its heart and results in enhanced IL-17A production.
